ArticleWorld journal of urology2025
Clinical efficacy of ozone therapy in managing category IIIB chronic prostatitis: symptom improvement and antioxidant effects.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter to the editor: "Clinical efficacy of ozone therapy in managing category IIIB chronic prostatitis: symptom improvement and antioxidant effects".World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) significantly affects quality of life, particularly in its non-inflammatory Category IIIB form. Ozone therapy has shown promise in various chronic diseases but remains underexplored in CP/CPPS. This study aimed to evaluate the efficacy of ozone therapy in improving urinary symptoms, sexual function, psychological well-being, and overall quality of life in patients with Category IIIB CP/CPPS.
methodsA retrospective analysis was conducted on 272 patients. The ozone therapy group (n = 152) received ten sessions of systemic major ozone therapy over five weeks, while the control group (n = 120) received no active treatment. Symptom severity and quality of life were assessed using validated clinical scales, and oxidative stress markers were measured at baseline and six weeks post-treatment.
resultsOzone therapy significantly improved clinical outcomes, reducing the International Prostate Symptom Score (22.95 to 11.38, p = 0.000) and the National Institutes of Health Chronic Prostatitis Symptom Index (25.34 to 15.88, p = 0.000), with significant improvements in pain, urinary symptoms, and quality of life subdomains. Additionally, the International Index of Erectile Function increased (15.30 to 20.88, p = 0.000), while the Aging Male Symptom Scale decreased (32.86 to 26.61, p = 0.000). Oxidative balance significantly improved, with Total Antioxidant Status increasing and Total Oxidant Status decreasing. Moreover, psychological well-being improved. In contrast, the control group showed minimal or no significant improvements.
conclusionsThese findings suggest that ozone therapy is safe, non-invasive, and effective treatment option for Category IIIB CP/CPPS, providing significant improvements in urinary symptoms, sexual function, quality of life, and psychological well-being, alongside a favorable shift in oxidative balance.
Indexed as
Identifiers
41269343What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.